NEW OCT SYSTEM SHOWS ENTIRE EYE
Researchers have developed an optical coherence tomography system that can provide a detailed image of the entire eye by incorporating a lens that changes optical parameters in response to an electric current. The researchers from Nicolaus Copernicus University in Poland and the Universidad de Murcia in Spain say the technology can produce higher quality images than currently available and could make eye examinations faster and more comfortable for patients by avoiding the need to undergo imaging with multiple instruments to look at different areas of the eye. In Optica, The Optical Society’s journal for high-impact research, the researchers show that their new OCT can image the front and the back of the eye and image the interfaces of the eye’s vitreous gel with the retina and lens in great detail. This new imaging capability could allow scientists to better understand how the vitreous gel that fills the eye interacts with the retina and why it can sometimes become detached with aging. Go to UMK.pl/en/.
FDA APPROVES RHOPRESSA FOR LOWERING IOP
The U.S. Food and Drug Administration has approved Rhopressa (netarsudil 0.02%) Aerie Pharmaceuticals’ eyedrop for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The once-a-day eyedrop increases the outflow of aqueous humor through the trabecular meshwork. Call 949.526.8700, or go to AeriePharma.com.
I-PEN TEAR OSMOLARITY SYSTEM COMES TO THE U.S.
A new distribution agreement between OCuSOFT Inc. and I-MED Pharma Inc., a Montreal-based biotechnology company, will make the I-PEN Osmolarity System available in the U.S., pending anticipated FDA 510(k) clearance in the first quarter of 2018. The I-PEN Tear Osmolarity system, used with the I-PEN Single Use Sensors, measures the tear-soaked palpebral conjunctiva and displays a numerical tear osmolarity test result on the liquid crystal display. Call 800.233.5469, or go to OCuSOFT.com.
BIO-TISSUE ANNOUNCES AMNIOTIC MEMBRANE RESULTS
Use of cryopreserved amniotic membrane and intraoperative mitomycin C reduces recurrence rates after pterygium surgery, according to study findings in the February 2018 issue of Cornea. In this retrospective review, 556 eyes of 535 patients who underwent pterygium excision were treated with Bio-Tissue Inc.’s AmnioGraft cryopreserved amniotic membrane. After an average follow-up period of 17.3 months, corneal recurrence occurred in only 20 eyes (3.6%) and conjunctival recurrence in 12 (2.2%) eyes, for a total recurrence rate of 5.8%. Call 888.296.8858 or go to BioTissue.com.
AMPLEYE SCLERAL LENS AVAILABLE IN TWO MORE DIAMETERS
With the addition of 15.0mm and 15.5mm diameters, Art Optical’s Ampleye scleral lens is now available in diameters from 15.0mm to 17.0mm. The reduced diameter Ampleye does not require additional diagnostic lenses—a simple sagittal depth conversion calculation from the 16.5mm Dx lens will produce the same initial fitting results—but for those who prefer to work with smaller scleral lenses, Art Optical offers nine-lens diagnostic sets in the 15.0mm and 15.5mm diameter. Ampleye lenses also feature anterior surface toric and multifocal optics, quadrant-specific control technology, and Tangible Hydra-Peg surface coating on lenses made in Optimum materials. Call 800.253.9364, or go to ArtOptical.com/Ampleye.
PHASE 2 DRY EYE TRIAL NOW UNDER WAY
Novaliq GmbH has begun randomization of patients in its multicenter SEECASE Phase 2 clinical trial for the treatment of dry eye disease. The SEECASE clinical trial, a randomized, double-masked, saline-controlled study, will evaluate the effect of using NOV03 either twice daily or four times daily to treat signs and symptoms of dry eye disease. NOV03 is designed to immediately stabilize the lipid layer and possibly dissolve lipids in the meibomian glands to improve their functionality. Go to Novaliq.com.
CooperVision, Inc., acquired Paragon Vision Sciences, a manufacturer of orthokeratology (ortho-k) and specialty contact lenses and gas-permeable contact lens materials.
The Centene Charitable Foundation, St. Louis, has provided a $150,000 grant to Optometry Cares—The Foundation’s InfantSEE program in which nearly 4,000 optometrists examine thousands of infants annually for normal eye development and to intervene early if necessary.
Shire plc announced that Xiidra (lifitegrast ophthalmic solution 5%), a twice-daily eyedrop solution indicated for treating the signs and symptoms of dry eye disease in adults, has been approved in Canada.
Momenta Pharmaceuticals, Inc. and Mylan N.V. announced plans for a randomized, double-blind, active-control, multi-center study to compare the safety, efficacy and immunogenicity of M710, a proposed biosimilar to EYLEA (aflibercept) injection, in patients with diabetic macular edema during the first half of 2018.
Glaukos Corp. announced that its Travoprost Intraocular Implant with the iDose delivery system continued to provide sustained reduction in intraocular pressure (IOP) in a 12-month interim cohort of patients in its U.S. Investigational New Drug (IND) Phase II clinical trial.